Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | Chief Financial Officer | December 22, 2020 | December 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date December 22, 2020 · Filed December 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,081 |
Ending reported balance
After 2020-12-22 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2020-12-22 · Exercise / conversion · Acquired 161,801 · Balance 445,882 Row 2 · 2020-12-22 · Exercise / conversion · Acquired 150,000 · Balance 595,882 Row 3 · 2020-12-22 · Exercise / conversion · Acquired 300,000 · Balance 895,882 Row 4 · 2020-12-22 · Exercise / conversion · Acquired 100,000 · Balance 995,882 Row 5 · 2020-12-22 · Sale · Disposed 245,704 · Balance 750,178 F1: The sale transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan the Reporting Person entered into on November 12, 2020. The plan provides for the periodic sales by the Reporting Person's broker without further action by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $5.03 to $5.98. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2020-12-22 · Sale · Disposed 453,997 · Balance 296,181 F3: This transaction was executed in multiple trades at prices ranging from $6.02 to $6.99. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2020-12-22 · Sale · Disposed 12,100 · Balance 284,081 |
| Non-qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2025-11-23 | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-22 · Exercise / conversion · Acquired 161,801 · Balance 0 |
| Non-qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2025-06-30 | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-22 · Exercise / conversion · Acquired 150,000 · Balance 0 |
| Non-qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-12-22 · Exercise / conversion · Acquired 300,000 · Balance 0 |
| Non-qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2022-12-13 | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-12-22 · Exercise / conversion · Acquired 100,000 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The sale transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan the Reporting Person entered into on November 12, 2020. The plan provides for the periodic sales by the Reporting Person's broker without further action by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $5.03 to $5.98. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $6.02 to $6.99. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · derivative · entry 11 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2022-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · derivative · entry 10 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · derivative · entry 9 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 161,801 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · derivative · entry 8 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 161,801 shares Expires 2025-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 12,100 | $7.00 | $84,700.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · nonDerivative · entry 7 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 453,997 | $6.61 | $3,003,008.56 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · nonDerivative · entry 6 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,181 F3 · price: This transaction was executed in multiple trades at prices ranging from $6.02 to $6.99. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 245,704 | $5.49 | $1,349,848.64 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · nonDerivative · entry 5 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,178 F1 · kind: The sale transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan the Reporting Person entered into on November 12, 2020. The plan provides for the periodic sales by the Reporting Person's broker without further action by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.03 to $5.98. The price above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 100,000 | $1.40 | $140,000.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · nonDerivative · entry 4 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 300,000 | $1.09 | $327,000.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · nonDerivative · entry 3 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 150,000 | $0.90 | $135,000.00 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · nonDerivative · entry 2 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 00:21 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 161,801 | $0.87 | $140,766.87 |
DisclosureSEC source: 0001807094-20-000031 · primary_doc.xml · nonDerivative · entry 1 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 88,199 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · derivative · entry 17 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,801 Underlying: Common Stock · 88,199 shares Expires 2025-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fifty percent (50%) of the reported option became fully vested in 2016 and 50% was forfeited. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · derivative · entry 16 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The reported option became fully vested on grant date. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 201,598 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · derivative · entry 15 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 201,598 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 585,797 | $5.58 | $3,269,918.85 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 10 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 F4 · price: This transaction was executed in multiple trades at prices ranging from $5.03 to $6.00. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 88,199 | $0.87 | $76,733.13 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 9 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 300,000 | $0.80 | $240,000.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 8 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 201,598 | $0.57 | $114,910.86 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 7 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 88,199 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · derivative · entry 17 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,801 Underlying: Common Stock · 88,199 shares Expires 2025-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fifty percent (50%) of the reported option became fully vested in 2016 and 50% was forfeited. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · derivative · entry 16 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The reported option became fully vested on grant date. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 201,598 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · derivative · entry 15 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 201,598 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | SaleCommon Stock | 589,797 | $5.58 | $3,292,246.85 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 10 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 F4 · price: This transaction was executed in multiple trades at prices ranging from $5.03 to $6.00. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionCommon Stock | 88,199 | $0.87 | $76,733.13 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 9 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionCommon Stock | 300,000 | $0.80 | $240,000.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 8 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionCommon Stock | 201,598 | $0.57 | $114,910.86 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 7 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 98,402 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · derivative · entry 14 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,598 Underlying: Common Stock · 98,402 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The reported option became fully vested on June 1, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 233,100 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · derivative · entry 13 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,900 Underlying: Common Stock · 233,100 shares Expires 2028-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Sixty-seven percent (67%) of the reported option became fully vested on June 8, 2020; the shares remaining subject to this option vest on June 8, 2021. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 155,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · derivative · entry 12 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,500 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 487,002 | $4.95 | $2,411,439.10 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 6 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 F3 · price: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.08. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 98,402 | $0.57 | $56,089.14 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 5 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 233,100 | $0.49 | $114,219.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 4 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 155,500 | $0.39 | $60,645.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 3 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 98,402 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · derivative · entry 14 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,598 Underlying: Common Stock · 98,402 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The reported option became fully vested on June 1, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 233,100 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · derivative · entry 13 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,900 Underlying: Common Stock · 233,100 shares Expires 2028-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Sixty-seven percent (67%) of the reported option became fully vested on June 8, 2020; the shares remaining subject to this option vest on June 8, 2021. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 155,500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · derivative · entry 12 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,500 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | SaleCommon Stock | 487,002 | $4.95 | $2,411,439.10 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 6 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 F3 · price: This transaction was executed in multiple trades at prices ranging from $4.80 to $5.08. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionCommon Stock | 98,402 | $0.57 | $56,089.14 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 5 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionCommon Stock | 233,100 | $0.49 | $114,219.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 4 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionCommon Stock | 155,500 | $0.39 | $60,645.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 3 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · derivative · entry 11 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,500 Underlying: Common Stock · 32,000 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reported option became fully vested on October 7, 2020. Read SEC document |
| December 17, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 32,000 | $4.55 | $145,673.60 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 2 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 F1 · kind: All shares sold and reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan the reporting person entered into on November 12, 2020. The plan provides for periodic sales by the reporting person's broker without further action by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.50 to $4.68. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 22, 2020 02:55 UTC Amendment | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 32,000 | $0.39 | $12,480.00 |
DisclosureSEC source: 0001807094-20-000030 · primary_doc.xml · nonDerivative · entry 1 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · derivative · entry 11 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,500 Underlying: Common Stock · 32,000 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reported option became fully vested on October 7, 2020. Read SEC document |
| December 17, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | SaleCommon Stock | 32,000 | $4.55 | $145,673.60 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 2 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 F1 · kind: All shares sold and reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan the reporting person entered into on November 12, 2020. The plan provides for periodic sales by the reporting person's broker without further action by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.50 to $4.68. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| December 17, 2020 Filed Dec 22, 2020 02:01 UTC | CytoDyn Inc. WAFD · Entity 5856 | Exercise / conversionCommon Stock | 32,000 | $0.39 | $12,480.00 |
DisclosureSEC source: 0001807094-20-000029 · primary_doc.xml · nonDerivative · entry 1 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 200,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001807094-20-000019 · primary_doc.xml · derivative · entry 2 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-06-15 F3 · date: The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the "Plan") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020. F4 · derivative.exercise_date: The stock option vests annually in three equal installments beginning June 15, 2021. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001807094-20-000019 · primary_doc.xml · nonDerivative · entry 1 Mulholland Michael D. · CIK 0001257911 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,081 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan. F2 · price: Not applicable. Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | Tax withholdingCommon Stock | 56,942 | $0.64 | $36,442.88 |
DisclosureSEC source: 0000899243-19-030131 · doc4.xml · nonDerivative · entry 2 Mulholland Michael D. · CIK 0001257911 · SVP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,081 Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 153,897 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-030131 · doc4.xml · nonDerivative · entry 1 Mulholland Michael D. · CIK 0001257911 · SVP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,023 F1 · price: The reported securities were granted in respect of an annual performance award for the fiscal year ended May 31, 2018, which had been previously approved but not yet issued. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:11 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030008 · doc4.xml · derivative · entry 1 Mulholland Michael D. · CIK 0001257911 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: One-half of the options vest immediately upon grant and one-half of the options will vest upon the achievement of certain additional strategic milestones specified in the award agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.